GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calithera Biosciences Inc (OTCPK:CALA) » Definitions » Shiller PE Ratio

Calithera Biosciences (Calithera Biosciences) Shiller PE Ratio : (As of May. 11, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Calithera Biosciences Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Calithera Biosciences Shiller PE Ratio Historical Data

The historical data trend for Calithera Biosciences's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calithera Biosciences Shiller PE Ratio Chart

Calithera Biosciences Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Calithera Biosciences Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Calithera Biosciences's Shiller PE Ratio

For the Biotechnology subindustry, Calithera Biosciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Calithera Biosciences's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Calithera Biosciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Calithera Biosciences's Shiller PE Ratio falls into.



Calithera Biosciences Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Calithera Biosciences's E10 for the quarter that ended in Dec. 2022 is calculated as:

For example, Calithera Biosciences's adjusted earnings per share data for the three months ended in Dec. 2022 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2022 (Change)*Current CPI (Dec. 2022)
=-1.45/125.2218*125.2218
=-1.450

Current CPI (Dec. 2022) = 125.2218.

Calithera Biosciences Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201212 0.000 96.871 0.000
201306 0.000 98.518 0.000
201309 -8.407 98.790 -10.656
201312 -10.355 98.326 -13.187
201403 -10.512 99.695 -13.204
201406 -6.915 100.560 -8.611
201409 -6.598 100.428 -8.227
201412 -7.616 99.070 -9.626
201503 -8.800 99.621 -11.061
201506 -8.800 100.684 -10.945
201509 -9.800 100.392 -12.224
201512 -8.800 99.792 -11.042
201603 -10.400 100.470 -12.962
201606 -11.000 101.688 -13.546
201609 -8.800 101.861 -10.818
201612 -9.000 101.863 -11.064
201703 -4.400 102.862 -5.356
201706 -3.000 103.349 -3.635
201709 -3.400 104.136 -4.088
201712 -6.200 104.011 -7.464
201803 -7.400 105.290 -8.801
201806 -1.800 106.317 -2.120
201809 -10.400 106.507 -12.227
201812 -10.200 105.998 -12.050
201903 -12.200 107.251 -14.244
201906 -11.600 108.070 -13.441
201909 -7.600 108.329 -8.785
201912 -7.800 108.420 -9.009
202003 -7.600 108.902 -8.739
202006 -5.800 108.767 -6.677
202009 -6.400 109.815 -7.298
202012 -6.400 109.897 -7.292
202103 -5.600 111.754 -6.275
202106 -3.860 114.631 -4.217
202109 -3.010 115.734 -3.257
202112 -18.400 117.630 -19.588
202203 -3.600 121.301 -3.716
202206 -1.590 125.017 -1.593
202209 -2.010 125.227 -2.010
202212 -1.450 125.222 -1.450

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Calithera Biosciences  (OTCPK:CALA) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Calithera Biosciences Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Calithera Biosciences's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Calithera Biosciences (Calithera Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
343 Oyster Point Boulevard, Suite 200, South San Francisco, CA, USA, 94080
Calithera Biosciences Inc is a clinical-stage pharmaceutical company. The business activity of the firm functions through the region of the United States. It focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. Its product candidate is CB-839, an inhibitor of glutaminase for the treatment of solid tumors. Its other product candidate, CB-1158, is being developed for hematology and oncology indications.
Executives
Deepika Pakianathan director, 10 percent owner 160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402
Takeda Ventures, Inc. 10 percent owner 9625 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Keith Orford officer: SR. VP, CLINICAL DEVELOPMENT CALITHERA BIOSCIENCES, 343 OYSTER POINT BLVD, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Jonathan G Drachman director 21823 30TH DRIVE SE, BOTHELL WA 98021
Susan Molineaux director, officer: PRESIDENT AND CEO C/O CALITHERA BIOSCIENCES, INC., 343 OYSTER POINT BLVD., SUITE 200, SOUTH SAN FRANCISCO CA 94080
Christopher Molineaux officer: SR. VP, DEVELOPMENT CALITHERA BIOSCIENCES, 343 OYSTER POINT, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Emil Kuriakose officer: CHIEF MEDICAL OFFICER 343 OYSTER POINT BLVD, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Millennium Pharmaceuticals Inc 10 percent owner 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Takeda Pharmaceutical Co Ltd 10 percent owner 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668
J. Scott Garland director 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Stephanie Wong officer: VP, FINANCE 343 OYSTER POINT BLVD #200, SOUTH SAN FRANCISCO CA 94080
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104

Calithera Biosciences (Calithera Biosciences) Headlines

From GuruFocus

Calithera Biosciences Announces 1-for-20 Reverse Stock Split

By GuruFocusNews GuruFocusNews 07-04-2022

Calithera Biosciences Announces Board Approval of Complete Liquidation and Dissolution

By Stock market mentor Stock market mentor 01-09-2023